A multidrug resistance transporter from human MCF-7 breast cancer cells

Greenebaum Cancer Center of the University of Maryland, Baltimore MD 21201, USA.
Proceedings of the National Academy of Sciences (Impact Factor: 9.81). 01/1999; 95(26):15665-70. DOI: 10.1073/pnas.95.26.15665
Source: PubMed

ABSTRACT MCF-7/AdrVp is a multidrug-resistant human breast cancer subline that displays an ATP-dependent reduction in the intracellular accumulation of anthracycline anticancer drugs in the absence of overexpression of known multidrug resistance transporters such as P glycoprotein or the multidrug resistance protein. RNA fingerprinting led to the identification of a 2.4-kb mRNA that is overexpressed in MCF-7/AdrVp cells relative to parental MCF-7 cells. The mRNA encodes a 655-aa [corrected] member of the ATP-binding cassette superfamily of transporters that we term breast cancer resistance protein (BCRP). Enforced expression of the full-length BCRP cDNA in MCF-7 breast cancer cells confers resistance to mitoxantrone, doxorubicin, and daunorubicin, reduces daunorubicin accumulation and retention, and causes an ATP-dependent enhancement of the efflux of rhodamine 123 in the cloned transfected cells. BCRP is a xenobiotic transporter that appears to play a major role in the multidrug resistance phenotype of MCF-7/AdrVp human breast cancer cells.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Traditional medicine of the Native Americans has a long tradition of medicinal plants, which also influenced modern oncology. For instance, podophyllotoxin the active ingredient of Podophyllum peltatum L. (Berberidaceae) used by Native Americans to treat warts led to the development of etoposide and teniposide. In the present investigation, we studied 10 medicinal plants used by the Gwich'in First Nation of West-Canada, which have been used against diverse diseases including cancer. Sensitive and multidrug-resistant (MDR) tumor cell lines expressing various ATP-binding cassette (ABC) transporters (P-glycoprotein/ABCB1/MDR1, MRP1/ABCC1, or BCRP/ABCG2) have been used. Cytotoxicity was determined by the resazurin assay. Arctium minus Bernh. (Asteraceae). Lysichiton americanus Hultén & St. John (Araceae), and Maianthemum dilatatum (Alph.Wood) A.Nelson & J.F.Macbr.(Asparagaceae) were cytotoxic with IC50 values ranging from 2.40 to 86.35 µg/mL. The MDR cell lines did not exert cross-resistance to these extracts. As these medicinal plants of the West-Canadian Gwich'in First Nation were not involved in classical drug resistance mechanisms and might therefore be valuable to bypass anticancer drug resistance in refractory tumors. Copyright © 2015. Published by Elsevier Ireland Ltd.
    Journal of ethnopharmacology 03/2015; 168. DOI:10.1016/j.jep.2015.03.052 · 2.94 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Irinotecan is a camptothecin analogue currently used in clinical practice to treat advanced colorectal cancer. However, acquired resistance mediated by the drug efflux pump ABCG2 is a recognized problem. We reported on a novel camptothecin analogue, FL118, which shows anticancer activity superior to irinotecan. In this study, we sought to investigate the potency of FL118 versus irinotecan or its active metabolite, SN-38, in both in vitro and in vivo models of human cancer with high ABCG2 activity. We also sought to assess the potency and ABCG2 affinity of several FL118 analogues with B-ring substitutions. Colon and lung cancer cells with and without ABCG2 overexpression were treated with FL118 in the presence and absence of Ko143, an ABCG2-selective inhibitor, or alternatively by genetically modulating ABCG2 expression. Using two distinct in vivo human tumor animal models, we further assessed whether FL118 could extend time to progression in comparison with irinotecan. Lastly, we investigated a series of FL118 analogues with B-ring substitutions for ABCG2 sensitivity. Both pharmacological inhibition and genetic modulation of ABCG2 demonstrated that, in contrast to SN-38, FL118 was able to bypass ABCG2-mediated drug resistance. FL118 also extended time to progression in both in vivo models by more than 50% compared with irinotecan. Lastly, we observed that FL118 analogues with polar substitutions had higher affinity for ABCG2, suggesting that the nonpolar nature of FL118 plays a role in bypassing ABCG2-mediated resistance. Our results suggest that in contrast to SN-38 and topotecan, FL118 is a poor substrate for ABCG2 and can effectively overcome ABCG2-mediated drug resistance. Our findings expand the uniqueness of FL118 and support continued development of FL118 as an attractive therapeutic option for patients with drug-refractory cancers resulting from high expression of ABCG2.
    Molecular Cancer 04/2015; 14(1):92. DOI:10.1186/s12943-015-0362-9 · 5.40 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Breast cancer resistance protein (BCRP) is a protein belonging to the ATP-binding cassette (ABC) transporter superfamily that has clinical relevance due to its multi-drug resistance properties in cancer. BCRP can be associated with clinical cancer drug resistance, in particular acute myelogenous or acute lymphocytic leukemias. The overexpression of BCRP contributes to the resistance of several chemotherapeutic drugs, such as topotecan, methotrexate, mitoxantrone, doxorubicin and daunorubicin. The Food and Drugs Administration has already recognized that BCRP is clinically one of the most important drug transporters, mainly because it leads to a reduction of clinical efficacy of various anticancer drugs through its ATP-dependent drug efflux pump function as well as its apparent participation in drug resistance. This review article aims to summarize the different research findings on marine natural products with BCRP inhibiting activity. In this sense, the potential modulation of physiological targets of BCRP by natural or synthetic compounds offers a great possibility for the discovery of new drugs and valuable research tools to recognize the function of the complex ABC-transporters.
    Marine Drugs 04/2015; 13(4):2010-2029. DOI:10.3390/md13042010 · 3.51 Impact Factor


Available from